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Abstract
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Antiretroviral therapy (ART) is known for its side effects. In this paper, we describe ART side
effects as experienced by Chinese HIV+ individuals. This study presents two stages of a research
project, combining qualitative in-depth interviews (29 HIV+ participants) with quantitative
statistical data analysis (N = 120). All data was collected between July 2005 to March 2008 at
Beijing's Ditan Hospital. Consent was obtained from each participant for the qualitative interview
and again for the quantitative survey. During in-depth interviews, Chinese HIV+ patients reported
experiencing digestive discomfort, skin rashes, numbness, memory loss, nightmares, and
dizziness, which not only brought them physical discomfort, but also interrupted different
dimensions of their social lives. Furthermore, multiple regression analyses revealed that those who
reported more severe side effects also experienced greater depressive mood after controlling for
other clinical and psychosocial factors. ART side effects are one of the primary reasons causing
HIV+ individuals to delay or stop taking life-saving medication; therefore, clinical interventions
are critically needed to assist HIV+ individuals in managing ART side effects. ART side effects
reinforced existing negative attitudes toward ART and lead to lower ART adherence. Future
research should focus on developing culturally sensitive interventions to enhance HIV+ selfmanagement, to alleviate physical and psychological burden from ART and HIV.
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Background
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Today, in the United States, 30 antiretroviral therapies (ART) made up of 23 separate drugs
are being used to control the HIV virus [1]. The growth in the number and kinds of
medications available to treat HIV/AIDS has changed the prospects for HIV/AIDS
management for both patients and providers. Treatment has gone from being a means of
temporary delay in the face of imminent death, to sustained management of HIV/AIDS as a
chronic, survivable disease [2]. Arrival of new treatment regimens, however, has come with
new complications. Given the increasing potential for negative drug-to-drug interactions and
the potential for multiple comorbidities, management of HIV patients has become a complex
affair.
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The Chinese national ART program, known as “Four Frees and One Care,” began in 2003,
and ART treatment is now widely available in China [3]. Initially, the only available
antiretroviral drugs in China were domestically produced generic zidovudine (ZDV),
stavudine (d4T), didanosine (ddI), and nevirapine (NVP). Approximately 80% of patients
received ZDV + ddI + NVP. The other 20% received d4T + ddI + NVP, primarily due to
hematologic contraindications or complications with ZDV. Domestically produced generic
indinavir (IDV) and imported, branded efavirenz (EFV), and lamivudine (3TC) were added
subsequently [4]. At present in China, although there are new medications available, overall
regimens used in these combinations have not changed significantly since 2007 [5].
Before 2003, most Chinese HIV/AIDS patients on ART were using imported drugs they had
obtained on their own. For example, friends might have brought the drugs back from
overseas or purchased them on the black market. With early results of treatments provided
by the “Four Frees and One Care” program [6], treatment was rapidly updated. By August
2008, more than 52,000 people had received first-line ART – about 97% of patients on
medications in China were receiving free treatment through Four Frees and One Care [7]. At
that time, the first-line treatment regimen of nucleoside reverse transcriptase inhibitors
(NRTI) consisted of zidovudine (AZT) or stavudine (d4T) with nevirapine (NVP), all
generically produced in China. The availability of free ART offered some flexibility in
treating patients; however, an effective second-line regimen did not exist until 2008 [4].
Didanosine (ddI, a generic drug) was used as the third-line treatment until 2009, when the
branded lamivudine (3TC) also became available [7]. Pare usually put on the first
combination of AZT/D4T+3TC+NVP/EFV. Then, the provider will adjust the combination
based on the patients’ tolerance and side effects. The regimen might be changed to second
line of the treatment if necessary [8].
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Despite these successes in increasing treatment accessibility and outcomes, treatments for
HIV have been well known for their severe side effects. For instance, the possible side
effects of nevirapine (NVP) include severe gastrointestinal reactions, peripheral neuritis, and
abnormal hepatic functions. Whitish plaques on the lips and bilateral buccal mucosa, as well
as a burning sensation, taste disturbance, and xerostomia have also been reported [9].
Another first-line treatment, stavudine (d4T), is known for causing a variety of systemic
discomforts, including mitochondrial toxicities (mainly peripheral neuropathies, lifethreatening lactic acidosis, and lipoatrophy) and metabolic dysfunctions (e.g. abdominal
obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting
glucose) [10]. These side effects are relatively frequent and worrisome, and have been
reported often in studies [11]. However, satisfactory virological efficacy has been achieved
in stavudine (d4T)-based combinations-d4T is usually combined with 3TC or NVP—and
these combinations have diminished toxicities and side effects [11]. Unfortunately, some of
these combinations might not be available in all parts of China at this time; therefore,
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Chinese patients taking ART may still need to tolerate side-effect syndromes of varying
degrees, ranging from mild to life threatening.
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Most of the studies related to side effects were conducted in Western countries, leaving a
gap in the experiences of side effects among people living with HIV/AIDS (PLWHA) in
countries with fewer resources, where generic drugs are integral parts of treatments. In one
prospective study, all the Chinese HIV+ patients receiving generic drugs developed at least
one episode of symptoms that could be attributed to treatment side effects, where about one
third of which were considered clinically severe [12].
Although some HIV+ patients can overcome initial side effects, without appropriate
treatments side effects may lead to challenging situations, including increasing stress and
depression, decreasing adherence, and quality of life. ART adherence is affected by
numerous psychological, social, and cultural factors. Indeed, several studies have reported
that ART side effects are one of the major reasons that people living with HIV/AIDS
(PLWHA) stop taking their HIV medication [13,14]. Interventions aiming to facilitate
patients’ self-management of side effects of ART could then help to maintain or improve
adherence levels. The physical and psychological demands of coping with ART side effects
can be overwhelming to patients and decrease their quality of life [15].
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Based on empirical evidence, researchers concluded that despite the fact that ART
treatments can reduce symptoms caused by HIV and other opportunistic infections, their
effects on improving patients’ quality of life may be “canceled” out by emerging toxicities
and side effects experienced by patients [16]. Therefore, symptom management intervention
for psychological distress and physiological fatigue should be key areas of focus to improve
quality of life in HIV+ populations [17].

Objectives
Given high prevalence of the various side effects among Chinese HIV+ patients [18,19], in
order to optimize AIDS care and probability of treatment success, it is necessary to
understand how they experience ART side effects in their day-to-day life. In this study we
aimed to explore how Chinese HIV+ patients experience ART side effects. Additionally, we
tested the relationships between the burden of side effects, quality of life, and depressive
symptomatology.

Methods
NIH-PA Author Manuscript

This study presents two stages of a research project. Qualitative in-depth interviews were
conducted in the first stage (2005-2006) to explore different dimensions of treatment
experiences among Chinese HIV+ patients; quantitative surveys were conducted in the
second stage of the study (2006-2008) to test potential relationships informed by the results
of the qualitative interviews. Both stages were conducted at Beijing's Ditan Hospital. Ditan
Hospital is one of the premier treatment centers for infectious diseases in China. Participants
who were receiving care from Ditan Hospital at their outpatient clinics as well as those who
were recently discharged from the hospital were all invited to participate in the study. Since
the overall ART regimens used in China have not changed much since 2007 [5], this study
remains highly relevant to the current situation of the Chinese HIV+ population.

Participants
The Institutional Review Boards (IRB) at Ditan Hospital and the University of Washington
approved all study procedures. Potential study participants were approached directly by
clinic staff and informed about the study; those who were interested were then referred to
J AIDS Clin Res. Author manuscript; available in PMC 2013 September 28.
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research staff. To ensure fidelity across clinic staff, a project manager was onsite to rescreen
the potential study participants after they were referred from clinical staff. After study
personnel explained the nature, and potential risks and benefits of the study, potential
participants who agreed to be part of the study gave written informed consent. Consent was
obtained from each participant for the qualitative interview and again before the
questionnaire was administered. Mandarin-speaking HIV+ patients were recruited separately
for the qualitative (N=29) and quantitative (N=120) stages of the study. Of the quantitative
survey participants, 70 of them had been using ART for less than 3 months and 50 of them
were taking ART longer than 3 months.
The inclusion criteria of the study were HIV+ patients on antiretroviral medications who are
18 years of age or older, Mandarin-speaking, and are receiving HIV-related care at Ditan
Hospital in out-patient clinics or right before the participants were discharged from the
AIDS floor. The exclusion criteria were physical incapacitation or psychological or
cognitive impairment that would prevent their participation in the study as informally
assessed by medical providers. These two stages were independently recruited from the
same research site; therefore, participants may or may not have participated in both stages.

Qualitative study
NIH-PA Author Manuscript

For the qualitative interviews, participants could choose whether or not to have their
interviews audio-recorded; if they declined, detailed notes were taken. All participants
received 100 RMB (~$16) for their participation in the semi-structured, in-depth interview
(Table 1).

Interview process
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We recruited 29 study participants in order to achieve what the authors determined as
conceptual data saturation. Interviews took approximately 1 hour and were conducted in a
private space at the hospital. Interviewers included Ditan Hospital research staff, physicians
and nurses at the hospital, and researchers from the University of Washington. All
interviewers were of Chinese background and conducted the interviews in Mandarin.
Interviewers first completed a 2-day training course led by qualitative research experts at a
local university to familiarize themselves with the goals of the study and to learn
standardized procedures for qualitative interviewing. Interviewers used an interview guide to
ensure that all of the following topics were discussed: HIV testing history, HIV serostatus
disclosure experience, social support, medication history, side effects, and ART adherence
(including medication access, facilitators and barriers to adherence, and self-efficacy). All
interviews except one were audio-recorded, and all were transcribed into Mandarin
verbatim.

Data analysis
Qualitative content analysis [20] and a commercial software package (Atlas.ti Version 6)
were used to facilitate data coding and analysis. Two Chinese-speaking investigators who
were trained in qualitative research methods independently reviewed the transcripts and
identified codes to represent various themes in the narratives. These two investigators then
reviewed and discussed their coding choices in order to resolve any discrepancies the
meaning and assignment of codes, and general patterns observed in the data. Then, after
codes were assigned and quotes were retrieved, the researchers presented general themes to
the healthcare providers and community members at Ditan Hospital, who confirmed that
these patterns were congruent with their experiences. This paper is based on a descriptive
thematic analysis of the codes related to patient experiences with ART side effects. The goal
is to explicate the range and meaning of related concepts in the participants’ narratives by
J AIDS Clin Res. Author manuscript; available in PMC 2013 September 28.
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using descriptive thematic analysis. The selected quotations were translated into English by
the two bilingual researchers who led this analysis.
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Quantitative study
In the quantitative study, we aim to evaluate the relationship between the burden of side
effects and depressive symptomatology. It is because if the Chinese PLWHA experienced in
a very negative way in which side effects of HAART not only induced physical discomforts,
but also influenced other domains of social life, it is very likely that the experiences of side
effects may also associate with their depressive symptomatology. Therefore, we hypothesize
that the greater burden the side effects experienced by the Chinese PLWHA, the more
depressive symptomatology they would express.
For the quantitative portion, study participants were recruited from the outpatient clinic and
AIDS patient floors connected to Ditan Hospital. Participants were required to be receiving
care at the hospital and using ART at the time of the study. A total of 120 patients provided
data. The study participants were recruited in the second stage which spanned across two
years after completion of the first stage. The questionnaire was designed by the research
team and was implemented in Chinese.

Measures
NIH-PA Author Manuscript

Sociodemographic variables
Participants’ age, gender, marital/partner status, education level, income, residency, and
employment status were collected via participant self-report.
ART knowledge, quality of life, depressive symptomology, side effects, and social support
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Researchers assessed participants’ knowledge about their medications using a validated HIV
Knowledge scale [21], with three additional items adapted from a related project via an inperson interview [22]. Scores were averaged on a 0-3 scale, with Cronbach's α = 0.73. The
quality of life was measured by the Medical Outcomes Study HIV Health Survey (MOSHIV) Chinese version. The MOS-HIV Chinese version was validated and had very good
psychometrics properties (Cronhach's αs ranged from 0.79 to 0.90) [23]. For the purpose of
this study, we created two composite measures for physical and mental quality of life,
following the standard procedures. The two composite measures both ranged from 0 to 100.
In addition, a revised 10-item version of the Center for Epidemiologic Studies Depression
Scale (CES-D) was used, as described in a related paper [24]. Cronbach's α for the CES-D
scale was 0.77. Researchers also administered a 20-item checklist via in-person interview to
assess presence of side effects, which included a question evaluating whether side effects
influence participants’ daily lives, ranging from 0 (not at all) to 4 (very much). If
participants indicated that they experienced side effects, we further explored the burden of
the current side effects. “Current side effect severity” was determined by an item that ranged
from 0 (not at all) to 4 (very much). Finally, researchers administered a 14-item checklist via
in-person interview to assess the types of social support participants had received from their
caregivers. The 14 items were added to derive an aggregate measure of the level of social
support (0-14). Cronbach's α for the social support scale was 0.75.
Missing values comprised about 10% of the sample. We have investigated the missing
mechanisms and concluded that “missing at random (MAR)” is a reasonable assumption for
this dataset, so we performed multiple imputations to handle the missing values. All the
statistical analysis was performed in STATA version 12, commercial statistical software.
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Results
Qualitative findings
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The sample comprised 29 HIV+ patients, of whom 7 were women and 22 were men. Most
of the sample (n=26, 90%) were ethnically Han, an ethnic group native to East Asia, and a
majority (n=22, 76%) lived in Beijing. The mean age of the study participants was 38 years.
Many had at least a high school education (n=20, 72%). Some of the participants (n=11,
38%) did not reveal their HIV transmission routes. Among those who did, sexual contact
(n=10, 34%) and blood-to-blood transmission (n=8, 28%) were the most common means of
transmission. Participants’ length of awareness of their HIV status ranged from 2 to 10
years. More than half (n=11, 59%) were married, and four reported that they were living
with a steady same-sex partner. Additional details of the population have been published
[25].
Twenty-one of these had been taking ART for longer than 6 months, and the other eight had
started ART within the previous 2 weeks. Several ART side effects were reported by the
study participants, including those with physiological and psychological symptoms. Below
are some of the ART-related discomforts that were often mentioned.

NIH-PA Author Manuscript

Digestive system—Digestive system issues like diarrhea, dry mouth, nausea, vomiting,
and weight loss/gain were most frequently mentioned. Although digestive side effects were
mild for most participants, for a few, the frequency and intensity were so severe that they
would use terms like “totally empty” to describe their state of mind after a serious episode.
Side effects this severe may even interfere with a patient's food intake and treatment
decisions. A 40-year-old male participant vividly shared his experience of diarrhea
I had severe diarrhea and lost a lot of weight. I must be dying. I couldn’t keep
anything down and I didn’t want to eat anything. [I kept eating] just because my
family kept telling me to think about my children; otherwise, I would not have
wanted to stay in the hospital and deal with the ART side effects.
The size of ART pills can also exacerbate a patient's digestive side effects. For example, the
didanosine (ddI) tablet is large to swallow, so to take this medication, one need to first chew
the tablet, during which time the taste and odor may trigger a nauseous reaction. As attested
by one 66-year-old patient “The pill is too big. After I chew that big tablet, I feel very
nauseous and have a stomach ache.”

NIH-PA Author Manuscript

Pancreatitis—A more serious kind of side effect impacted a few patients. It has been well
documented that some HIV medications, such as didanosine (ddI) and stavudine (d4T), can
cause more severe side effects like pancreatitis, which results from the interaction between
the ingredients in the medicine and certain digestive enzymes [26,27]. Without appropriate
treatment, pancreatitis can be lethal. A 30-year-old male described his experiences, which
started with acute abdominal pain:
I was suffering severe pain from noon to midnight. I couldn't tolerate it anymore, so
I came into the emergency room here. I was . . . diagnosed with pancreatitis. They
[physicians] checked my enzymes. Some of the enzymes were normal and some
were not . . . They all believed these symptoms were side effects from ART. And I
heard that chewing the tablet in my [ART] combination is bad for the pancreas.
The pain caused by pancreatitis can be so intense that it can overwhelm the ability of
narcotics to suppress it. One interviewee perceived his experiences of hospitalization
through the prism of pain brought on by acute pancreatitis: “I was constantly given the pain
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medicine,” he said, “and I still remember that the pain kept me awake, even with all those
narcotics.”
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Dermatological symptoms—The second most complained about side effect was skin
issues, including, but not limited to, change of skin tone, skin rashes, and hair loss. For
instance, a 37-year-old female told us that after she started ART, she noticed her skin
turning black and looking like charcoal. The darkening of skin tone occurred not just on her
trunk but also on her face, which was understandably very distressing to her. Other skinrelated side effects included uncomfortable sensations and itches. Participants complained of
a burning and tingling sensation all over their bodies. Besides the physical discomfort they
cause, skin-related side effects may have significant implications for patients’ social lives,
especially in China, where HIV stigma is still rampant. Visible changes to a patient's skin
may be perceived by others as a “mark of disease” and may solicit unwanted attention. One
42-year-old male participant decided to wear long sleeves constantly, even during summer,
because of skin rashes on his arms. During his interview, which occurred in late summer, he
pointed to his unseasonal clothing, said:

NIH-PA Author Manuscript

Did you wonder why I am not wearing short sleeves? It is because those scars are
still there, so I can only wear long-sleeved shirts. I wish summer would go faster,
especially when I see my coworkers wearing shorts and tank tops, while I have to
have my long sleeves on. People keep asking me: “Hey, don't you feel hot?” I
always tell them that I am allergic to sunlight.
Neurological symptoms—Many study participants also complained of numbness, using
a variety of illuminating metaphors to describe their feelings. Among these was “a sensation
of electric shock,” “being frozen,” “like wearing tight shoes,” and “walking barefoot on a
gravel path.” While many of the participants stated that the numbness was usually constant
and long lasting, it could become worse during sleep. The feeling of numbness could be
mingled with other unpleasant sensations, such as soreness and throbbing pain, which
prevented patients from getting restful sleep at night. One 46-year-old male participant
described how the spreading and encroaching numbness had caused him insomnia for
several nights:
The numbness crept up from my feet and spread out over my body. Just like with
an electrical shock, the feet feel it the worst. During the night, my feet are so sore,
numb, and swollen that I can hardly sleep. The pain is so constant. I can hardly
close my eyes.
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Numbness can interrupt patients’ daily activities in serious ways. Because it affects mostly
patients’ feet and hands, it may reduce their ability to carrying out their job duties. This is
exemplified by the description of a 32-year-old female participant, who stated that she was
“suffering from side effects [numb feet] every minute of every day.” Because the side
effects were very serious in her case, she was confined to her bed and could not work to
support herself. To alleviate numbness, interviewees tried different strategies, including
massage therapy and wearing softer shoes, although most of these efforts were in vain.
Some patients had to change their regimens to get relief from the side effects.
Memory loss, nightmares, and dizziness—Some of the patients complained about
symptoms associated with the central nervous system (CNS), including memory loss,
nightmare, and dizziness. A 28-year-old male participant stated that he used to have a sharp
memory, but after he initiated ART treatment, he began suffering from partial memory loss.
A 37-year-old female patient said that when she took efavirenz (EFV), she was so dizzy she
could hardly stand. To her it was as if “the sky was falling down.” She also began to have
nightmares that significantly decreased her sleep quality. As a result, she had to spend most
J AIDS Clin Res. Author manuscript; available in PMC 2013 September 28.
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of her time in bed and so was unable to work. Another 66-year-old male participant echoed
her experience. This participant had suffered from dizziness as an ART side effect for more
than 6 months. The dizziness was so bad it interfered with his work, he told the interviewer.
“I feel so light. My brain is empty, and I have no energy to do anything. This is not the way
it should be.”
Quantitative findings
A total of 142 eligible participants were invited to participate in the study, and 120 of them
agreed to participate, for an 85% recruitment rate. The sample was 82% (N=98) male, with a
mean age of 36 years (SD = 8.0). Slightly more than half (54%; N=65) of the participants
were working, and 55% (N=66) reported that they were married or had a steady partner.
Nearly all study participants (93%; N=112) were of Han ethnicity, and close to two thirds
(62%; N=74)) had finished high school. Detailed demographic information is presented in
Table 2.
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Within this sample, 53.3% (N=64) had experienced digestive side effects; 51.7% (N=62)
had skin-related symptoms; 36.1% (N=43) had numbness in hands and feet; and 73.6%
(N=88) had memory loss, nightmares, and/or dizziness. Because pancreatitis requires
official diagnosis from a physician, we did not track this information in the dataset;
however, 41.9% (N=50) of our sample reported experiencing some kind of stomach ache in
connection with the ART.
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We conducted bivariate analysis to explore the relationships between depressive mood,
burden of side-effects, psychosocial factors, demographic data, CD4 values, and medication
combinations. Detailed information related to side-effect severity is presented in Table 2.
Then, we used multivariate multiple linear regression to further investigate the relationship
between depressive mood, quality of life, and perceived burden of side effects, adjusting for
the effects of covariates and confounders, such as stigma, ART knowledge, and social
support. As expected, the distribution of depression (CES-D) scores was highly skewed, so
the Yeo-Johnson procedure was used to transform the dependent variable to make its
distribution more reasonably normal. The scores for the physical and mental quality of life
had reasonably normal distributions. The results of the model fitting are presented in the
Table 3. Except for the finding that age is marginally significantly related to CES-D, none of
the demographic and clinical factors were related to the CES-D scores. Although ART
knowledge significantly related to CES-D scores in the bivariate analysis, the relationship
was no longer significant when other factors were controlled for. By contrast, the perceived
burden of side effects was significantly associated with CES-D scores. Finally, social
support and general health also had significant relationships with a patient's depressive
mood, although they were entered into the model only to adjust the relationship between
CES-D and side effects and were not our primary interest.

Discussion
In the current study, we documented how Chinese PLWHA experienced side effects of
ART. These side effects not only brought physical pain and discomfort but also affected
many aspects of daily life. Certain CNS-related discomforts induced by ART-conditions
such as memory loss, dizziness, and numb feet- could, in their more extreme forms, impinge
upon Chinese PLWHA's daily functioning and prevent them from conducting regular
activities necessary to support themselves and their families. These symptoms are similar to
those reported by other studies conducted in China [18].
In addition, many Chinese PLWHAs in this study expressed that therapy-related alterations
in their appearance can exacerbate existing HIV stigma to increase psychological burden. As
J AIDS Clin Res. Author manuscript; available in PMC 2013 September 28.
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a result, they may need to fabricate reasonable excuses to explain their changing appearance
or the unseasonable clothing they may use to hide their dermatological symptoms. Given
that ART side effects could interfere with a wide range of dimensions of daily life among
Chinese PLWHA, depression can be another pernicious consequence of ART side effects.
From this study, surprisingly, none of the demographic variables, CD4 values, or medication
combinations had significant relationships with depressive mood. In contrast, all of the
psychosocial factors, except for HIV stigma, had significant relationships with depressive
mood. In particular, patients who received more social support, had greater knowledge of
their medications, and enjoyed better general health, were less depressed. In addition, those
who reported greater burden of side effects tended to report more depressed mood.
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As ART side effects have the capacity to bring Chinese PLWHA many challenges that have
significant social and cultural implications, it is expected that those facing greater burdens of
side effects would experience greater depressive mood. Although the relationship between
depressive symptomatology and experienced ART side effects has not been a traditional
research focus, our findings are consistent with existing literature. Low-Beer and colleagues
found that participants’ depressive symptomatology deteriorated after they initiated protease
inhibitors-based treatments [28]. This was especially salient for those who enjoyed higher
quality of life before their treatments; their depressive symptomatology deteriorated along
with three other dimensions of quality of life (physical, social, and role functions) [28].
Another study also reported that personal experience of ART-related side effects and
depression were highly associated in HIV+ individuals [29]. Thus, developing clinical
interventions that address self-management of side effects is greatly needed. Interventions
that focus on psychosocial factors, enhance protective health routines, and reduce risk
behaviors (e.g. drug holidays) are likely to lessen overall morbidity and mortality among
patients living with HIV/AIDS [30]. Therefore, providing a manual of self-management for
ART side effects could help patients deal with the discomfort of these side effects. At the
same time, it could decrease side-effect related depression.
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In Chinese culture, the concept of health encompasses fulfillment of obligations to support
family. Not being able to carry out one's duties or to maintain harmonious relationships with
others in one's social network is considered to be socially “unhealthy” in Chinese culture
[31]. Consequently, there is a significant social cost to ART side effects in addition to the
physical and psychological ones. Compromised social functioning induced by ART side
effects may further render some Chinese PLWHA to lose faith in their regimens while
driving some others to seek help from Complementary and Alternative Medicine (CAM)
[14,32]. Since allopathic medicine (like ART) is thought by many Chinese individuals to
cause disruption in the body's yin/yang balance, it is believed to cause harm to the body, and
this harm is seen as being evidenced by side-effects. In fact, for many Chinese PLWHA,
ART is seen as being akin to poison [14]. Experience of side effects can thus significantly
predict Chinese PLWHA's preference for CAM over ART. Many Chinese PLWHA who
embrace allopathic medicine and ART may also use CAM to manage their experienced sideeffects [14]. They believe that CAM can compensate for the toxicity and yin/yang imbalance
caused by ART and can therefore decrease side effects [14].
Currently, metabolic syndromes (e.g. abdominal obesity, hypertriglyceridemia, low HDL
cholesterol, high blood pressure, and high fasting glucose) related to ART use are rarely
addressed in developing countries like China. These side effects have caused PLWHAs in
China to change behaviors including using CAM more frequently and altered their self
image. Switching drugs (for example, switching stavudine (d4T) to another Nucleoside
Reverse Transcriptase Inhibitor (NRTI)) would be one acceptable alternative that could be
used to alleviate such syndromes. However, clinicians need to confirm the availability of
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alternative NRTIs in their particular facility, country, or region before proposing a change
between medicines or combinations. Behavior and diet changes can moderate side effects as
well, which are especially attractive alternatives in resource-limited settings, where drugswitching options are limited [11]. For example, efforts as simple as getting regular exercise
and limiting high-cholesterol foods can prevent dyslipidemic side effects [33]. Studies have
shown that symptom management interventions have been effective at increasing self-care
ability in managing medication side effects with HIV+ individuals [34]. Also, depression
and catastrophizing pain were proofed as important factors in managing HIV-related
neuropathy and ART adherence [35]. Furthermore, Mediterranean-style diets (e.g., eating
primarily plant-based foods, such as fruits and vegetables, whole grains, legumes and nuts,
replacing butter with healthy fats, such as olive oil, using herbs and spices instead of salt to
flavor foods, limiting red meat to no more than a few times a month, eating fish and poultry
at least twice a week or drinking red wine in moderation (optional)) were found to be
effective in improving the HIV-associated lipodystrophy syndrome [36]. Thus, we
recommend that self-management programs for side effects be applied in clinical practice
generally.

Limitations

NIH-PA Author Manuscript

There were several limitations in this study. First, we recruited only at one large hospital, in
Beijing, China. Since Beijing is a metropolitan area and the capital city, it has better
resources for Chinese PLWHA than most other areas. Second, as the disease progress from
HIV to AIDS, patients might develop opportunistic diseases whose symptoms (for example,
fatigue and sleeplessness) can mimic ART side effects. As researchers, we were not always
able to differentiate between symptoms related to disease progression and ART side effects.
Third, by the time of the quantitative phase of the study, some of the participants had been
using ART for longer than 6 months, and they might not have remembered some of the
initial ART side effects that they experienced. Some of them who had skipped this part of
the questionnaire may have done so in error, thinking that they had not experienced side
effects, when in fact they had. Fourth, the acceptable internal consistency score on several
scales used in this project indicate the cultural adaptations of these scales need to be further
investigated. Last, the Chinese government was aware of these side effects from ART, thus,
efforts were made to change the formulation of first-line ART treatment in order to decrease
side effects.

Conclusion
NIH-PA Author Manuscript

As we discovered in this study, the symptoms of ART side effects have biological,
psychological, and social dimensions that impact Chinese PLWHA in unique ways. To some
extent, ART side effects can be moderated, but even so, side effects remain a part of the
comprehensive illness experience. Without careful management, side effects can reinforce
existing negative attitudes and ultimately lead to lower ART adherence levels. Future
research should focus on developing culturally sensitive interventions to enhanced selfmanagement that can alleviate the physical and psychological burdens from ART and from
the disease.
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Table 1

Qualitative In-depth Interview Schedule.
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Warm up

Let's start by having you tell me a little about yourself. How are you feeling today? How has your health been lately?
Could you tell me something about your experience with HIV/AIDS?
Could you tell me something about your experience with HIV medications?
From your understanding, how do Anti-retroviral medications work?
What do you think will make it hard for you to take your medications? Or what has made it hard in the past?
Some circumstances that may make it difficult for some people to take medications. Let me ask how you think these would apply
to you.
a. Side effects from HIV medications
b. Depression: Can you describe a time when you (your partner) felt sad, felt like you (he/she) did not want to eat, or experienced
feelings of depression? If so please tell me about you (your partner) experience.
a. Stigma (having to hide)
b. Access to medication or medical care
c. Financial problems
Finally, please tell us a little about yourself? For example....

NIH-PA Author Manuscript

a. Where are you from, what province?
b. What is your ethnicity?
c. What is your age?
d. What was the last year you finished ofschool?
e. What was your last job?
f. Who lives in your household?
g. At home do you have your own room or do you share a room with others?
h. Do you have a male or female spouse or partner?
i. Is there anything else you would like to share with us about using HIV medications?
Closing

Ok. That's it for our questions. Do you have anything else to add or anything else to ask me?
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Table 2

Sample Background Characteristics and their Relationship to Quality of Life and CESD, (N = 120).
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Total

Physical QoL

Mental QoL

CES-D

Percentage(N)

Mean

SE

Mean

SE

Mean

SE

Female

18.3 (22)

43.94

2.91

45.67

2.32

3.61

0.42

Male

81.7 (98)

45.94

1.11

49.03

1.08

3.54

0.18

< HS

38.3 (46)

48.35

1.59

48.68

1.47

3.35

0.28

HS

37.5 (45)

44.58

1.71

49.16

1.71

3.65

0.28

> HS

24.2 (29)

2.11

46.81

2.15

3.75

0.31

Gender

Education

*

42.70

Current Residency
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Urban

63.3 (76)

44.64

1.23

48.67

1.28

3.50

0.21

Suburban

17.5 (21)

46.41

2.51

49.11

2.25

3.64

0.33

Rural

19.2 (23)

47.88

2.44

46.93

2.16

3.67

0.40

Professional

33.9 (41)

44.94

1.95

48.05

1.66

3.50

0.26

Manual Labor

15.0 (18)

48.86

3.06

47.47

2.36

3.18

0.46

Freelancer

19.4 (23)

46.75

1.29

48.99

1.83

3.55

0.32

Not Working

31.7 (38)

44.49

2.00

49.38

2.04

3.73

0.34

Married/Partnered

55.0 (66)

44.27

1.69

47.06

1.48

3.79

0.23

Other

45.0 (54)

46.63

1.34

49.51

1.32

3.37

0.23

< 2000 RMB/month

41.7 (50)

46.58

1.56

47.99

1.27

3.55

0.23

> 2001 RMB/month

58.3 (70)

44.57

1.32

49.37

1.56

3.52

0.24

58.3 (70)

49.53

1.06

48.66

1.12

3.41

0.21

1.90

48.06

1.80

3.76

0.26

Work Status

Relationship Status

Household Income

Time on ART
=< 6 months
> 6 months

41.7 (50)

**

40.02
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ART Combination
AZT + NVP + 3TC

52.5 (63)

45.85

1.49

48.20

1.30

3.64

0.23

AZT + EFV + 3TC

22.5 (27)

48.77

1.70

48.17

1.88

3.59

0.31

All others

25.0 (30)

42.60

2.19

49.66

2.46

3.40

0.38

CD4 Rank
< 200

40.0 (48)

44.65

1.51

48.93

1.53

3.68

0.22

200 – 350

36.7 (44)

46.73

1.99

48.36

1.82

3.39

0.31

351 – 500

16.7 (20)

47.53

2.05

50.96

2.31

3.23

0.52

6.6 (8)

45.83

4.48

45.67

4.30

3.73

0.58

Mean (SD)

β

SE

β

SE

β

SE

> 500
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Total

Physical QoL

Mental QoL

CES-D

Percentage(N)

Mean

SE

Mean

SE

Mean

Age

36.3 (.73)

0.03

0.13

0.17

0.12

Social Support

51.3 (1.8)

HIV Stigma

24.8 (.57)

ART Knowledge

2.08 (.03)

Side-Effect Severity

2.00 (.07)

**

0.05

*

0.16

0.19

−0.36
3.33

3.04

**

−7.46

1.23

**

0.15

−0.17

0.05
0.17

**

2.88

**

1.28

10.07

−7.04

SE

†

0.02

**

0.01

−0.03
−0.02
0.03

0.03

†

0.49

**

0.20

−0.84
1.12

Physical QoL = Physical Quality of Life; Mental QoL = Mental Quality of Life; CES-D = Transformed Center for Epidemiologic Studies
Depression Scale; SE = Standard Error; HS = High school; RMB = Renminbi, Chinese unit of currency;Zidovudine (AZT);Nevirapine (NVP);
lamivudine (3TC); Efavirenz (EFV).

**

P< 0.01

*

P< 0.05

†

P< 0.1
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Table 3

Predictors of Quality of Life and CESD among 120 HIV-Positive Individuals in China.
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Physical QoL
β

SE

**

Constant

63.38

Age

8.71

0.06

0.12

2.86

2.69

Mental QoL
β
41.18

**

CES-D

SE

β

SE

10.78

2.81

1.78

†

0.02

2.74

−0.47

0.47

2.29

0.27

0.39

†

0.46

0.19

0.14

†

0.19

−0.04

Gender
Female vs. Male

5.07

Time on ART
=< 6 months vs. > 6 months

**

−7.88

2.28

ART Combination

†

AZT + NVP + 3TC vs. AZT + EFV + 3TC

−1.68

2.26

AZT + NVP + 3TC vs. All others

0.55

2.12

0.89

2.52

−0.35

0.43

< 200 vs. 200 – 350

−1.02

2.16

−3.26

2.40

0.12

0.41

< 200 vs. 351 – 500

−2.57

2.66

−2.36

2.99

0.28

0.53

< 200 vs. > 500

0.07

3.41

−4.54

3.86

0.01

0.68

ART Knowledge

−1.22

2.73

4.19

3.21

0.05

0.57

*

0.05

*

0.06

−0.21

0.15

−0.18

0.18

−4.89

2.62

0.87

CD4 Rank
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Social Support
HIV Stigma
Side-Effect Severity

0.13

**

−6.85

1.23

0.12

**

−6.35

1.40

*

−0.02
0.03

**

1.12

0.01
0.03
0.24

β = Estimated Coefficient Correlation; SE = Standard Error; Physical QoL = Physical Quality of Life; Mental QoL = Mental Quality of Life;
CES-D = Transformed Center for Epidemiologic Studies Depression Scale;Zidovudine (AZT); Nevirapine (NVP); lamivudine (3TC); Efavirenz
(EFV). All the models were further adjusted for covariates listed in table 2.

**

P< 0.01

*

p< 0.05

†

p< 0.1
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